Vir Biotechnology VIR shares are trading higher on Monday, after the company announced plans to work on coronavirus solutions with GlaxoSmithKline and a $250 million investment from the company.
Vir Biotechnology is a clinical-stage immunology company, developing therapeutic products to treat and prevent serious infectious diseases. The company has grant agreements with Bill & Melinda Gates Foundation.
Vir Biotechnology shares traded up 16.48% to $33.78 at time of publication on Monday. The stock has a 52-week high of $75 and a 52-week low of $11.65.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
